Grenada Heart Project–Community Health ActioN to EncouraGe healthy BEhaviors (GHP-CHANGE): A randomized control peer group–based lifestyle intervention - 05/02/20
Abstract |
Background |
The incidence of cardiovascular (CV) risk factors is increasing globally, with a disproportionate burden in the low and low-middle income countries (L/LMICs). Peer support, as a low-cost lifestyle intervention, has succeeded in managing chronic illness. For global CV risk reduction, limited data exists in LMICs.
Aim |
The GHP-CHANGE was designed as a community-based randomized trial to test the effectiveness of peer support strategy for CV risk reduction in the island of Grenada, a LMIC.
Methods |
We recruited 402 adults from the Grenada Heart Project (GHP) Cohort Study of 2827 subjects with at least two CV risk factors. Subjects were randomized in a 1:1 fashion to a peer-group based intervention group (n = 206) or a self-management control group (n = 196) for 12 months. The primary outcome was the change from baseline in a composite score related to Blood pressure, Exercise, Weight, Alimentation and Tobacco (FBS, Fuster-BEWAT Score), ranging from 0 to 15 (ideal health = 15). Linear mixed-effects models were used to test for intervention effects.
Results |
Participants mean age was 51.4 years (SD 14.5) years, two-thirds were female, and baseline mean FBS was 8.9 (SD 2.6) and 8.5 (SD 2.6) in the intervention and control group, respectively (P = .152). At post intervention, the mean FBS was higher in the intervention group compared to the control group [9.1 (SD 2.7) vs 8.5 (SD 2.6), P = .028]. When balancing baseline health profile, the between-group difference (intervention vs. control) in the change of FBS was 0.31 points (95% CI: −0.12 to 0.75; P = .154).
Conclusions |
The GHP-CHANGE trial showed that a peer-support lifestyle intervention program was feasible; however, it did not demonstrate a significant improvement in the FBS as compared to the control group. Further studies should assess the effects of low-cost lifestyle interventions in LMICs.
Le texte complet de cet article est disponible en PDF.Abbreviations : CV, LMICs, WHO, GHP, GHP-CHANGE, BMI, FBS
Plan
| Trial registration: ClinicalTrials.gov identifier NCT02428920. Registered (NCT02428920). |
|
| Funding: This study was funded by the Louis B Mayer Foundation. VF is a recipient of funding from the American Heart Association under grant No 14SFRN20490315. R.F-J is a recipient of funding from the European Union Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 707642. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). |
|
| Disclosures: Authors declare no relationship with industry or other relevant entities that might pose a conflict of interest in connection with the submitted article. This trial is registered at clinicaltrials.gov under NCT02428920. |
Vol 220
P. 20-28 - février 2020 Retour au numéro
Article précédent
- Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people
- Aldo P. Maggioni, Letizia Dondi, Felicita Andreotti, Antonella Pedrini, Silvia Calabria, Giulia Ronconi, Carlo Piccinni, Nello Martini
- Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial
- Rachael Ward, Zhen Huang, Frank W. Rockhold, Iris Baumgartner, Jeffrey S. Berger, Juuso I. Blomster, F. Gerry R. Fowkes, Brian G. Katona, Kenneth W. Mahaffey, Lars Norgren, Sreekanth Vemulapalli, Thomas J. Povsic, Rajendra Mehta, William R. Hiatt, Manesh R. Patel, W. Schuyler Jones
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?